• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Preventive Vaccine Market

    ID: MRFR/Pharma/41679-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Preventive Vaccine Market Research Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Toxoid Vaccines), By Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal), By Target Disease (Viral Infections, Bacterial Infections, Parasitic Infections, Fungal Infections), By End User (Hospitals, Clinics, Pharmacies, Home Care Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Preventive Vaccine Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Preventive Vaccine Market Summary

    The Global Preventive Vaccine Market is projected to grow from 42.5 USD Billion in 2024 to 65 USD Billion by 2035.

    Key Market Trends & Highlights

    Preventive Vaccine Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 3.95% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 65 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 42.5 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of preventive healthcare measures due to increased awareness of vaccine benefits is a major market driver.

    Market Size & Forecast

    2024 Market Size 42.5 (USD Billion)
    2035 Market Size 65 (USD Billion)
    CAGR (2025-2035) 3.95%

    Major Players

    Novavax, Moderna, Vaxart, Johnson and Johnson, Merck and Co, Pfizer, BristolMyers Squibb, GlaxoSmithKline, AbbVie, Bayer, Sanofi, Takeda, Regeneron, AstraZeneca, Seqirus

    Preventive Vaccine Market Trends

    The Preventive Vaccine Market has experienced significant growth due to various key market drivers. The increasing prevalence of infectious diseases, along with growing awareness about the importance of vaccination, has propelled demand. Governments and health organizations are investing more in immunization programs, focusing on preventative measures to enhance public health.

    Additionally, advancements in vaccine technology and the rise of public-private partnerships have further stimulated market growth, allowing for the development of more effective vaccines. Opportunities within the market are abundant, particularly in the area of vaccine innovation.

    Developing vaccines for emerging pathogens and enhancing the efficiency of vaccine distribution can open new avenues for growth. As global travel increases and new diseases are discovered, there is a pressing need for vaccines that can respond quickly to these threats. Furthermore, collaborations with biotech firms and research institutions are essential in developing next-generation vaccines.

    Expanding access to vaccines in underserved populations presents another potential area for market expansion, ensuring equitable healthcare. Trends in recent times indicate a shift toward personalized medicine and more targeted vaccine approaches. The integration of advanced technologies, such as mRNA platforms, has paved the way for quicker and more adaptable vaccine creation. There is also a growing interest in preventive health measures driven by consumer demand for healthier lifestyles.

    Public awareness campaigns are increasingly focused on the necessity and safety of vaccines, leading to better public perception and acceptance. This trend underscores the importance of continuous education about vaccine benefits, which is essential for maintaining high vaccination rates and overall community health.

    The global preventive vaccine market is poised for robust growth as increasing awareness of vaccine-preventable diseases drives demand for immunization across diverse populations.

    World Health Organization (WHO)

    Preventive Vaccine Market Drivers

    Market Growth Chart

    Rising Global Disease Burden

    The increasing prevalence of infectious diseases worldwide drives the Global Preventive Vaccine Market Industry. As populations grow and urbanization expands, the risk of disease outbreaks escalates. For instance, the World Health Organization indicates that vaccine-preventable diseases still account for a significant number of deaths annually. This trend necessitates the development and distribution of vaccines, contributing to the market's projected value of 42.5 USD Billion in 2024. The urgency to combat diseases such as measles and polio underscores the importance of vaccines, fostering a robust demand for preventive measures across various demographics.

    Government Initiatives and Funding

    Government initiatives play a pivotal role in shaping the Global Preventive Vaccine Market Industry. Many countries are increasing their investments in vaccination programs to enhance public health outcomes. For example, national immunization programs often receive substantial funding to ensure widespread vaccine access. The commitment to immunization is reflected in the projected market growth, with an expected value of 65 USD Billion by 2035. Such initiatives not only facilitate vaccine development but also promote public awareness, thereby driving demand for preventive vaccines and ensuring that populations remain protected against infectious diseases.

    Global Collaboration and Partnerships

    International collaboration among governments, NGOs, and pharmaceutical companies is vital for the Global Preventive Vaccine Market Industry. Partnerships facilitate resource sharing, research, and development, leading to more effective vaccine distribution strategies. Initiatives like GAVI, the Vaccine Alliance, exemplify how global partnerships can enhance vaccine access in low-income countries. Such collaborations are essential for addressing global health disparities and ensuring that vaccines reach vulnerable populations. As these partnerships expand, they are expected to contribute to the market's growth, reinforcing the importance of collective efforts in combating infectious diseases.

    Increased Public Awareness and Education

    Public awareness regarding the importance of vaccination is a crucial driver of the Global Preventive Vaccine Market Industry. Educational campaigns by health organizations and governments have led to higher vaccination rates and greater acceptance of vaccines. This heightened awareness is particularly evident in regions previously resistant to vaccination due to misinformation. As communities become more informed about the benefits of preventive vaccines, the demand for these products is likely to rise. Consequently, the market is projected to grow significantly, aligning with the overall trend of increasing health consciousness among global populations.

    Technological Advancements in Vaccine Development

    Technological innovations significantly influence the Global Preventive Vaccine Market Industry. Advances in biotechnology and genomics have accelerated vaccine development processes, allowing for quicker responses to emerging infectious diseases. For instance, mRNA technology has revolutionized vaccine design, enabling the rapid creation of effective vaccines. This technological shift is expected to contribute to a compound annual growth rate of 3.95% from 2025 to 2035, reflecting the industry's adaptability and responsiveness to global health challenges. As new technologies emerge, they enhance the efficacy and safety of vaccines, further driving market growth.

    Market Segment Insights

    Preventive Vaccine Market Vaccine Type Insights

    The Preventive Vaccine Market is characterized by a diverse array of vaccine types, each contributing uniquely to market dynamics. By 2024, the Live Attenuated Vaccines segment holds a notable valuation of 10.14 USD Billion, and this is projected to escalate to 16.15 USD Billion by 2035, showcasing its significant role in disease prevention through the use of weakened forms of pathogens.

    Similarly, Inactivated Vaccines reflect a robust market position, starting at 12.92 USD Billion in 2024 and anticipated to rise to 20.23 USD Billion by 2035, as they are crucial for immunization against various viral and bacterial infections, thereby fostering a substantial demand in healthcare settings.

    The Subunit Vaccines segment, valued at 6.42 USD Billion in 2024, is expected to reach 9.95 USD Billion by 2035, emphasizing its importance in providing targeted immune responses without the risks associated with live pathogens. mRNA Vaccines, valued at 7.98 USD Billion in 2024, are rapidly becoming a dominant force due to their innovative technology and effectiveness in combating emerging infectious diseases, with a projection of 12.29 USD Billion by 2035.

    Toxoid Vaccines, while the least valued at 5.0 USD Billion in 2024 are anticipated to grow to 6.38 USD Billion by 2035, underscoring their critical role in immunizing against toxins produced by pathogens.

    The market growth in these segments is driven by increasing awareness of vaccine benefits, government initiatives, and advancements in vaccine technology. However, challenges such as vaccine hesitancy and distribution logistics may impact growth rates.

    Preventive Vaccine Market Route of Administration Insights

    The Preventive Vaccine Market is steadily evolving within various routes of administration as each method offers distinct advantages that enhance vaccine delivery effectiveness. The route of administration significantly influences patient compliance and vaccine efficacy, with intramuscular administration holding a majority share due to its deep tissue absorption and systemic immune response generation.

    Subcutaneous administration also plays a vital role, providing an alternative for products that require less invasive delivery methods. Oral administration is gaining traction, particularly in pediatric vaccine distribution, as it simplifies dosing and enhances adherence among younger demographics.

    Intranasal routes are emerging as innovative solutions, allowing for non-invasive delivery and potentially increasing vaccination rates. Trends in the market are driven by advancements in delivery technologies and increased awareness of vaccination importance, while challenges such as vaccine hesitancy and logistical issues in distribution pose noteworthy barriers.

    The growth of the Global Preventive Vaccine Market continues to be supported by increasing investments in vaccine development and a global focus on immunization initiatives.

    Preventive Vaccine Market Target Disease Insights

    The market demonstrates a steady growth trajectory, supported by a CAGR of 3.94 from 2025 to 2035, reflecting the increasing demand for vaccination against various diseases. The market segmentation encompasses Viral Infections, Bacterial Infections, Parasitic Infections and Fungal Infections. Viral Infections, a critical focus area, dominate due to their widespread impact, contributing to health burdens globally.

    Bacterial Infections also hold significant relevance, as they are primary targets of preventive strategies to reduce morbidity rates. Similarly, Parasitic Infections require attention due to their persistent prevalence in certain regions, highlighting the need for effective vaccines.

    Fungal Infections, while less prevalent, are gaining recognition as emerging health concerns, driving research and development efforts in vaccine creation. With advancements in biotechnology, there are vast opportunities to enhance the efficacy and accessibility of vaccines in these segments, as reflected in the Global Preventive Vaccine Market data and statistics.

    Growing public health initiatives and awareness further facilitate market growth and foster innovations within the Global Preventive Vaccine Market.

    Preventive Vaccine Market End User Insights

    The End User segmentation is crucial for understanding market dynamics, as it includes key players such as hospitals, clinics, pharmacies, and home care settings. Hospitals dominate this segment due to their comprehensive patient care and vaccination programs, which play a significant role in administering preventive vaccines.

    Clinics also contribute substantially as they are accessible avenues for vaccinations, promoting community health. Pharmacies are becoming increasingly important in delivering vaccines conveniently, enhancing accessibility for patients.

    Home care settings offer personalized vaccination services, especially for the elderly and immobile patients, thereby broadening the market’s reach. The rising awareness of vaccine benefits and increasing healthcare initiatives are key growth drivers, while logistical challenges and vaccine hesitancy present notable hurdles.

    With robust Global Preventive Vaccine Market data, stakeholders can leverage this information to harness growth opportunities in this vital segment of the Global Preventive Vaccine Market.

    Get more detailed insights about Preventive Vaccine Market Research Report — Global Forecast till 2035

    Request Free Sample

    Regional Insights

    The Global Preventive Vaccine Market showcases significant regional variations in revenue generation, highlighting the importance of each area. North America leads with a market valuation of 18.2 USD Billion in 2024, predicted to rise to 28.5 USD Billion by 2035, largely due to advanced healthcare infrastructure and increased vaccine uptake.

    Europe follows with a value of 12.0 USD Billion in 2024 and is expected to reach 18.0 USD Billion in 2035, driven by governmental initiatives and strong public health systems, making it a significant contributor.

    The Asia-Pacific (APAC) region, valued at 8.5 USD Billion in 2024, anticipates growth to 13.0 USD Billion by 2035 as emerging markets improve their healthcare access and vaccination programs.

    Meanwhile, South America holds a smaller share, with a market value of 2.5 USD Billion in 2024, expected to expand to 3.9 USD Billion by 2035, facilitated by regional collaborations and increasing awareness about vaccination benefits. The Middle East and Africa (MEA), with 1.26 USD Billion in 2024, projected to grow to 1.7 USD Billion in 2035, represent the least dominant segment, facing challenges such as logistical hurdles and lower healthcare spending.

    This regional segmentation emphasizes varying capabilities and market growth potential within the Global Preventive Vaccine Market.

    Preventive Vaccine Market Region

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Preventive Vaccine Market is characterized by a rapidly evolving landscape where innovation, strategic partnerships, and technological advancements play pivotal roles in determining market dynamics. Companies are facing challenges such as stringent regulatory requirements, competition from biosimilars, and the need for effective vaccine delivery systems.

    The market encompasses a wide array of vaccines aimed at preventing infectious diseases, which is driven by increasing incidences of diseases, growing awareness regarding vaccination, and governmental initiatives promoting immunization.

    The competitive landscape is influenced by factors such as research and development investments, capabilities in clinical trial management and geographic reach. Companies must constantly adapt to changing epidemiological trends and consumer demands in order to maintain their leading positions in the sector.

    Novavax has established a significant presence within the Global Preventive Vaccine Market, known for its innovative approach developing vaccine candidates utilizing its proprietary nanoparticle technology. The company excels in the rapid formulation of vaccines, which has become especially relevant with the emergence of new infectious diseases.

    The strength of Novavax lies in its robust research and development pipeline, backed by substantial funding from governmental and strategic partners. Their emphasis on creating effective adjuvants that enhance immune responses demonstrates their commitment to developing vaccines that provide both efficacy and safety.

    Furthermore, Novavax's versatility in responding to evolving public health needs has allowed them to play a crucial role in vaccine development against emerging pathogens, positioning the company favorably in this competitive market.

    Moderna, another major player in the Global Preventive Vaccine Market, has revolutionized the industry with its pioneering mRNA technology, which has demonstrated remarkable efficacy in the rapid development of vaccines.

    The company's strength lies in its ability to swiftly develop and manufacture vaccines, making it a crucial contributor to global efforts to combat infectious diseases. Moderna's foundation in biomedical research, combined with its strategic collaborations and partnerships, has enabled it to expand its pipeline beyond COVID-19 vaccines to address other infectious diseases.

    Their focus on scalable production and distribution capabilities also highlights their proactive approach ensuring that vaccines are accessible to a wider population. The agility and innovative mindset that characterize Moderna's operations continue to set them apart in the competitive landscape of the Global Preventive Vaccine Market, making them a prominent force in addressing global health challenges.

    Key Companies in the Preventive Vaccine Market market include

    Industry Developments

    • Q3 2023: U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Maternal Immunization In August 2023, Pfizer announced that the U.S. FDA approved ABRYSVO™, a vaccine for preventing RSV in infants via active immunization of pregnant individuals at 32–36 weeks of gestational age.
    • Q2 2022: GSK’s Priorix receives US FDA approval for prevention of measles, mumps, and rubella in individuals aged 12 months and older In June 2022, GSK revealed that its vaccine Priorix received approval from the US FDA for the prevention of measles, mumps, and rubella in individuals aged 12 months and older.

    Future Outlook

    Preventive Vaccine Market Future Outlook

    The Global Preventive Vaccine Market is projected to grow at a 3.95% CAGR from 2024 to 2035, driven by technological advancements, increased healthcare spending, and rising awareness of preventive healthcare.

    New opportunities lie in:

    • Invest in mRNA technology for rapid vaccine development and production.
    • Expand vaccine access in emerging markets through strategic partnerships.
    • Leverage digital health platforms for vaccine education and tracking.

    By 2035, the market is expected to be robust, reflecting increased investment and innovation in preventive vaccines.

    Market Segmentation

    Preventive Vaccine Market End User Outlook

    • Hospitals
    • Clinics
    • Pharmacies
    • Home Care Settings

    Preventive Vaccine Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Preventive Vaccine Market Vaccine Type Outlook

    • Live Attenuated Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • mRNA Vaccines
    • Toxoid Vaccines

    Preventive Vaccine Market Target Disease Outlook

    • Viral Infections
    • Bacterial Infections
    • Parasitic Infections
    • Fungal Infections

    Preventive Vaccine Market Route of Administration Outlook

    • Intramuscular
    • Subcutaneous
    • Oral
    • Intranasal

    Report Scope

    Attribute/Metric Source: Details
    MARKET SIZE 2023 40.85(USD Billion)
    MARKET SIZE 2024 42.46(USD Billion)
    MARKET SIZE 2035 65.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 3.94% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Novavax, Moderna, Vaxart, Johnson and Johnson, Merck and Co, Pfizer, BristolMyers Squibb, GlaxoSmithKline, AbbVie, Bayer, Sanofi, Takeda, Regeneron, AstraZeneca, Seqirus
    SEGMENTS COVERED Vaccine Type, Route of Administration, Target Disease, End User, Regional
    KEY MARKET OPPORTUNITIES Rising demand for childhood vaccinations, Increased focus on global health security, Innovative vaccine technologies development, Expanding elderly population vaccination programs, Government incentives for vaccine research
    KEY MARKET DYNAMICS Rising infectious disease incidence, Increasing government immunization programs, Advancements in vaccine technology, Growing awareness of vaccine benefits, Expanding global healthcare access
    COUNTRIES COVERED North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the Global Preventive Vaccine Market in 2024?

    The Global Preventive Vaccine Market is expected to be valued at 42.46 billion USD in 2024.

    What is the projected market size for the Global Preventive Vaccine Market by 2035?

    By 2035, the Global Preventive Vaccine Market is projected to reach 65.0 billion USD.

    What is the expected CAGR for the Global Preventive Vaccine Market from 2025 to 2035?

    The Global Preventive Vaccine Market is expected to grow at a CAGR of 3.94% from 2025 to 2035.

    Which region holds the largest market share in the Global Preventive Vaccine Market for 2024?

    In 2024, North America holds the largest market share, valued at 18.2 billion USD.

    What will be the market size for Inactivated Vaccines in 2035?

    The market size for Inactivated Vaccines is expected to reach 20.23 billion USD by 2035.

    Who are the key players in the Global Preventive Vaccine Market?

    Key players in the Global Preventive Vaccine Market include Novavax, Moderna, Johnson and Johnson, and Pfizer.

    What is the market value of Live Attenuated Vaccines in 2024?

    The market value for Live Attenuated Vaccines is 10.14 billion USD in 2024.

    How much is the market for mRNA Vaccines expected to grow by 2035?

    The market for mRNA Vaccines is expected to grow to 12.29 billion USD by 2035.

    Which region is projected to have the fastest growth in the Global Preventive Vaccine Market?

    The Asia-Pacific (APAC) region is projected to grow from 8.5 billion USD in 2024 to 13.0 billion USD by 2035.

    What challenges may affect the growth of the Global Preventive Vaccine Market?

    Challenges may include regulatory hurdles and the adaptability of vaccine technologies.

    1. Primary Interviews and Information Gathering Process 3.4.2. Breakdown of Primary
    2. Respondents 3.5. Forecasting Model 3.6. Market Size Estimation 3.6.1. Bottom-Up
    3. Approach 3.6.2. Top-Down Approach 3.7. Data Triangulation 3.8. Validation 4. MARKET
    4. DYNAMICS 4.1. Overview 4.2. Drivers 4.3. Restraints 4.4. Opportunities 5. MARKET FACTOR ANALYSIS 5.1. Value chain Analysis 5.2. Porter's Five Forces Analysis 5.2.1.
    5. Bargaining Power of Suppliers 5.2.2. Bargaining Power of Buyers 5.2.3. Threat of
    6. New Entrants 5.2.4. Threat of Substitutes 5.2.5. Intensity of Rivalry 5.3. COVID-19
    7. Impact Analysis 5.3.1. Market Impact Analysis 5.3.2. Regional Impact 5.3.3. Opportunity
    8. and Threat Analysis 6. PREVENTIVE VACCINE MARKET, BY VACCINE TYPE (USD BILLION)
      1. Live Attenuated Vaccines 6.2. Inactivated Vaccines 6.3. Subunit Vaccines 6.4.
    9. mRNA Vaccines 6.5. Toxoid Vaccines 7. PREVENTIVE VACCINE MARKET, BY ROUTE OF ADMINISTRATION
    10. (USD BILLION) 7.1. Intramuscular 7.2. Subcutaneous 7.3. Oral 7.4. Intranasal 8.
    11. PREVENTIVE VACCINE MARKET, BY TARGET DISEASE (USD BILLION) 8.1. Viral Infections
      1. Bacterial Infections 8.3. Parasitic Infections 8.4. Fungal Infections 9. PREVENTIVE
    12. VACCINE MARKET, BY END USER (USD BILLION) 9.1. Hospitals 9.2. Clinics 9.3. Pharmacies
      1. Home Care Settings 10. PREVENTIVE VACCINE MARKET, BY REGIONAL (USD BILLION)
      2. North America 10.1.1. US 10.1.2. Canada 10.2. Europe 10.2.1. Germany 10.2.2.
    13. UK 10.2.3. France 10.2.4. Russia 10.2.5. Italy 10.2.6. Spain 10.2.7. Rest of Europe
      1. APAC 10.3.1. China 10.3.2. India 10.3.3. Japan 10.3.4. South Korea 10.3.5.
    14. Malaysia 10.3.6. Thailand 10.3.7. Indonesia 10.3.8. Rest of APAC 10.4. South America
      1. Brazil 10.4.2. Mexico 10.4.3. Argentina 10.4.4. Rest of South America 10.5.
    15. MEA 10.5.1. GCC Countries 10.5.2. South Africa 10.5.3. Rest of MEA 11. COMPETITIVE LANDSCAPE 11.1. Overview 11.2. Competitive Analysis 11.3. Market share Analysis
      1. Major Growth Strategy in the Preventive Vaccine Market 11.5. Competitive Benchmarking
      2. Leading Players in Terms of Number of Developments in the Preventive Vaccine
    16. Market 11.7. Key developments and growth strategies 11.7.1. New Product Launch/Service
    17. Deployment 11.7.2. Merger & Acquisitions 11.7.3. Joint Ventures 11.8. Major
    18. Players Financial Matrix 11.8.1. Sales and Operating Income 11.8.2. Major Players
    19. R&D Expenditure. 2023 12. COMPANY PROFILES 12.1. Novavax 12.1.1. Financial Overview
      1. Products Offered 12.1.3. Key Developments 12.1.4. SWOT Analysis 12.1.5.
    20. Key Strategies 12.2. Moderna 12.2.1. Financial Overview 12.2.2. Products Offered
      1. Key Developments 12.2.4. SWOT Analysis 12.2.5. Key Strategies 12.3. Vaxart
        1. Financial Overview 12.3.2. Products Offered 12.3.3. Key Developments 12.3.4.
    21. SWOT Analysis 12.3.5. Key Strategies 12.4. Johnson and Johnson 12.4.1. Financial
    22. Overview 12.4.2. Products Offered 12.4.3. Key Developments 12.4.4. SWOT Analysis
      1. Key Strategies 12.5. Merck and Co 12.5.1. Financial Overview 12.5.2. Products
    23. Offered 12.5.3. Key Developments 12.5.4. SWOT Analysis 12.5.5. Key Strategies 12.6.
    24. Pfizer 12.6.1. Financial Overview 12.6.2. Products Offered 12.6.3. Key Developments
      1. SWOT Analysis 12.6.5. Key Strategies 12.7. BristolMyers Squibb 12.7.1. Financial
    25. Overview 12.7.2. Products Offered 12.7.3. Key Developments 12.7.4. SWOT Analysis
      1. Key Strategies 12.8. GlaxoSmithKline 12.8.1. Financial Overview 12.8.2.
    26. Products Offered 12.8.3. Key Developments 12.8.4. SWOT Analysis 12.8.5. Key Strategies
      1. AbbVie 12.9.1. Financial Overview 12.9.2. Products Offered 12.9.3. Key Developments
        1. SWOT Analysis 12.9.5. Key Strategies 12.10. Bayer 12.10.1. Financial Overview
        2. Products Offered 12.10.3. Key Developments 12.10.4. SWOT Analysis 12.10.5.
    27. Key Strategies 12.11. Sanofi 12.11.1. Financial Overview 12.11.2. Products Offered
      1. Key Developments 12.11.4. SWOT Analysis 12.11.5. Key Strategies 12.12.
    28. Takeda 12.12.1. Financial Overview 12.12.2. Products Offered 12.12.3. Key Developments
      1. SWOT Analysis 12.12.5. Key Strategies 12.13. Regeneron 12.13.1. Financial
    29. Overview 12.13.2. Products Offered 12.13.3. Key Developments 12.13.4. SWOT Analysis
      1. Key Strategies 12.14. AstraZeneca 12.14.1. Financial Overview 12.14.2.
    30. Products Offered 12.14.3. Key Developments 12.14.4. SWOT Analysis 12.14.5. Key Strategies
      1. Seqirus 12.15.1. Financial Overview 12.15.2. Products Offered 12.15.3. Key
    31. Developments 12.15.4. SWOT Analysis 12.15.5. Key Strategies 13. APPENDIX 13.1. References
      1. Related Reports LIST OF TABLES TABLE 1. LIST OF ASSUMPTIONS TABLE 2. NORTH
    32. AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE,
    33. 2035 (USD BILLIONS) TABLE 3. NORTH AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    34. & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 4. NORTH
    35. AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE,
    36. 2035 (USD BILLIONS) TABLE 5. NORTH AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    37. & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 6. NORTH AMERICA PREVENTIVE
    38. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
    39. TYPE, 2019-2035 (USD BILLIONS) TABLE 8. US PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    40. & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 9. US
    41. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035
    42. (USD BILLIONS) TABLE 10. US PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    43. BY END USER, 2019-2035 (USD BILLIONS) TABLE 11. US PREVENTIVE VACCINE MARKET SIZE
    44. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 12. CANADA
    45. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    46. (USD BILLIONS) TABLE 13. CANADA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    47. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 14. CANADA PREVENTIVE
    48. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    49. BILLIONS) TABLE 15. CANADA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    50. BY END USER, 2019-2035 (USD BILLIONS) TABLE 16. CANADA PREVENTIVE VACCINE MARKET
    51. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 17. EUROPE
    52. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    53. (USD BILLIONS) TABLE 18. EUROPE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    54. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 19. EUROPE PREVENTIVE
    55. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    56. BILLIONS) TABLE 20. EUROPE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    57. BY END USER, 2019-2035 (USD BILLIONS) TABLE 21. EUROPE PREVENTIVE VACCINE MARKET
    58. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 22. GERMANY
    59. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    60. (USD BILLIONS) TABLE 23. GERMANY PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    61. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 24. GERMANY
    62. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035
    63. (USD BILLIONS) TABLE 25. GERMANY PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    64. FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 26. GERMANY PREVENTIVE VACCINE
    65. MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE
    66. UK PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE,
    67. 2035 (USD BILLIONS) TABLE 28. UK PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    68. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 29. UK PREVENTIVE
    69. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    70. BILLIONS) TABLE 30. UK PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    71. BY END USER, 2019-2035 (USD BILLIONS) TABLE 31. UK PREVENTIVE VACCINE MARKET SIZE
    72. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 32. FRANCE
    73. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    74. (USD BILLIONS) TABLE 33. FRANCE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    75. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 34. FRANCE PREVENTIVE
    76. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    77. BILLIONS) TABLE 35. FRANCE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    78. BY END USER, 2019-2035 (USD BILLIONS) TABLE 36. FRANCE PREVENTIVE VACCINE MARKET
    79. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 37. RUSSIA
    80. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    81. (USD BILLIONS) TABLE 38. RUSSIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    82. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 39. RUSSIA PREVENTIVE
    83. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    84. BILLIONS) TABLE 40. RUSSIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    85. BY END USER, 2019-2035 (USD BILLIONS) TABLE 41. RUSSIA PREVENTIVE VACCINE MARKET
    86. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 42. ITALY
    87. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    88. (USD BILLIONS) TABLE 43. ITALY PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    89. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 44. ITALY PREVENTIVE
    90. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    91. BILLIONS) TABLE 45. ITALY PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    92. BY END USER, 2019-2035 (USD BILLIONS) TABLE 46. ITALY PREVENTIVE VACCINE MARKET
    93. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 47. SPAIN
    94. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035
    95. (USD BILLIONS) TABLE 48. SPAIN PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    96. BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 49. SPAIN PREVENTIVE
    97. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD
    98. BILLIONS) TABLE 50. SPAIN PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    99. BY END USER, 2019-2035 (USD BILLIONS) TABLE 51. SPAIN PREVENTIVE VACCINE MARKET
    100. SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 52. REST
    101. OF EUROPE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE,
    102. 2035 (USD BILLIONS) TABLE 53. REST OF EUROPE PREVENTIVE VACCINE MARKET SIZE
    103. ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE
    104. REST OF EUROPE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET
    105. DISEASE, 2019-2035 (USD BILLIONS) TABLE 55. REST OF EUROPE PREVENTIVE VACCINE MARKET
    106. SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 56. REST
    107. OF EUROPE PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL,
    108. 2035 (USD BILLIONS) TABLE 57. APAC PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    109. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 58. APAC PREVENTIVE
    110. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    111. (USD BILLIONS) TABLE 59. APAC PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    112. BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 60. APAC PREVENTIVE VACCINE MARKET
    113. SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 61. APAC
    114. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    115. (USD BILLIONS) TABLE 62. CHINA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    116. BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 63. CHINA PREVENTIVE VACCINE MARKET
    117. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    118. DISEASE, 2019-2035 (USD BILLIONS) TABLE 65. CHINA PREVENTIVE VACCINE MARKET SIZE
    119. ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 66. CHINA
    120. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    121. (USD BILLIONS) TABLE 67. INDIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    122. BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 68. INDIA PREVENTIVE VACCINE MARKET
    123. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    124. DISEASE, 2019-2035 (USD BILLIONS) TABLE 70. INDIA PREVENTIVE VACCINE MARKET SIZE
    125. ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 71. INDIA
    126. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    127. (USD BILLIONS) TABLE 72. JAPAN PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    128. BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 73. JAPAN PREVENTIVE VACCINE MARKET
    129. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    130. DISEASE, 2019-2035 (USD BILLIONS) TABLE 75. JAPAN PREVENTIVE VACCINE MARKET SIZE
    131. ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 76. JAPAN
    132. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035
    133. (USD BILLIONS) TABLE 77. SOUTH KOREA PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    134. FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 78. SOUTH KOREA PREVENTIVE
    135. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    136. (USD BILLIONS) TABLE 79. SOUTH KOREA PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    137. FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 80. SOUTH KOREA PREVENTIVE
    138. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    139. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 82. MALAYSIA PREVENTIVE VACCINE MARKET
    140. SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 83.
    141. MALAYSIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    142. 2035 (USD BILLIONS) TABLE 84. MALAYSIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    143. & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 85. MALAYSIA PREVENTIVE
    144. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    145. 2035 (USD BILLIONS) TABLE 87. THAILAND PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    146. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 88. THAILAND PREVENTIVE
    147. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    148. (USD BILLIONS) TABLE 89. THAILAND PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    149. FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 90. THAILAND PREVENTIVE
    150. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    151. 2035 (USD BILLIONS) TABLE 92. INDONESIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    152. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 93. INDONESIA PREVENTIVE
    153. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    154. (USD BILLIONS) TABLE 94. INDONESIA PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    155. FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 95. INDONESIA PREVENTIVE
    156. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    157. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 97. REST OF APAC PREVENTIVE VACCINE MARKET
    158. SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 98.
    159. REST OF APAC PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF
    160. ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 99. REST OF APAC PREVENTIVE VACCINE
    161. MARKET SIZE ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS)
    162. BY END USER, 2019-2035 (USD BILLIONS) TABLE 101. REST OF APAC PREVENTIVE VACCINE
    163. MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE
    164. SOUTH AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE
    165. TYPE, 2019-2035 (USD BILLIONS) TABLE 103. SOUTH AMERICA PREVENTIVE VACCINE MARKET
    166. SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
    167. BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 105. SOUTH AMERICA PREVENTIVE
    168. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    169. BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 107. BRAZIL PREVENTIVE VACCINE MARKET
    170. SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 108.
    171. BRAZIL PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    172. 2035 (USD BILLIONS) TABLE 109. BRAZIL PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    173. & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 110. BRAZIL PREVENTIVE
    174. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    175. 2035 (USD BILLIONS) TABLE 112. MEXICO PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    176. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 113. MEXICO PREVENTIVE
    177. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    178. (USD BILLIONS) TABLE 114. MEXICO PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    179. FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 115. MEXICO PREVENTIVE
    180. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    181. 2035 (USD BILLIONS) TABLE 117. ARGENTINA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    182. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 118. ARGENTINA PREVENTIVE
    183. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035
    184. (USD BILLIONS) TABLE 119. ARGENTINA PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    185. FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 120. ARGENTINA PREVENTIVE
    186. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    187. REGIONAL, 2019-2035 (USD BILLIONS) TABLE 122. REST OF SOUTH AMERICA PREVENTIVE VACCINE
    188. MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS)
    189. FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE 124. REST OF
    190. SOUTH AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET
    191. DISEASE, 2019-2035 (USD BILLIONS) TABLE 125. REST OF SOUTH AMERICA PREVENTIVE VACCINE
    192. MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE
    193. REST OF SOUTH AMERICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST,
    194. BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 127. MEA PREVENTIVE VACCINE MARKET SIZE
    195. ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 128. MEA
    196. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    197. 2035 (USD BILLIONS) TABLE 129. MEA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    198. & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 130. MEA PREVENTIVE
    199. VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
    200. 2035 (USD BILLIONS) TABLE 132. GCC COUNTRIES PREVENTIVE VACCINE MARKET SIZE
    201. ESTIMATES & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 133. GCC
    202. COUNTRIES PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    203. 2035 (USD BILLIONS) TABLE 134. GCC COUNTRIES PREVENTIVE VACCINE MARKET SIZE
    204. ESTIMATES & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 135.
    205. GCC COUNTRIES PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER,
    206. 2035 (USD BILLIONS) TABLE 136. GCC COUNTRIES PREVENTIVE VACCINE MARKET SIZE
    207. ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 137. SOUTH
    208. AFRICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY VACCINE TYPE,
    209. 2035 (USD BILLIONS) TABLE 138. SOUTH AFRICA PREVENTIVE VACCINE MARKET SIZE
    210. ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS) TABLE
    211. SOUTH AFRICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY TARGET
    212. DISEASE, 2019-2035 (USD BILLIONS) TABLE 140. SOUTH AFRICA PREVENTIVE VACCINE MARKET
    213. SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS) TABLE 141.
    214. SOUTH AFRICA PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL,
    215. 2035 (USD BILLIONS) TABLE 142. REST OF MEA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    216. & FORECAST, BY VACCINE TYPE, 2019-2035 (USD BILLIONS) TABLE 143. REST OF MEA
    217. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION,
    218. 2035 (USD BILLIONS) TABLE 144. REST OF MEA PREVENTIVE VACCINE MARKET SIZE ESTIMATES
    219. & FORECAST, BY TARGET DISEASE, 2019-2035 (USD BILLIONS) TABLE 145. REST OF MEA
    220. PREVENTIVE VACCINE MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035
    221. (USD BILLIONS) TABLE 146. REST OF MEA PREVENTIVE VACCINE MARKET SIZE ESTIMATES &
    222. FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS) TABLE 147. PRODUCT LAUNCH/PRODUCT
    223. DEVELOPMENT/APPROVAL TABLE 148. ACQUISITION/PARTNERSHIP LIST OF FIGURES FIGURE 1.
    224. MARKET SYNOPSIS FIGURE 2. NORTH AMERICA PREVENTIVE VACCINE MARKET ANALYSIS FIGURE
    225. US PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 4. US PREVENTIVE
    226. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 5. US PREVENTIVE VACCINE
    227. MARKET ANALYSIS BY TARGET DISEASE FIGURE 6. US PREVENTIVE VACCINE MARKET ANALYSIS
    228. BY END USER FIGURE 7. US PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 8.
    229. CANADA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 9. CANADA PREVENTIVE
    230. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 10. CANADA PREVENTIVE
    231. VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 11. CANADA PREVENTIVE VACCINE MARKET
    232. ANALYSIS BY END USER FIGURE 12. CANADA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL
    233. VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 15. GERMANY PREVENTIVE VACCINE MARKET
    234. ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 16. GERMANY PREVENTIVE VACCINE MARKET
    235. ANALYSIS BY TARGET DISEASE FIGURE 17. GERMANY PREVENTIVE VACCINE MARKET ANALYSIS
    236. BY END USER FIGURE 18. GERMANY PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE
    237. UK PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 20. UK PREVENTIVE
    238. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 21. UK PREVENTIVE VACCINE
    239. MARKET ANALYSIS BY TARGET DISEASE FIGURE 22. UK PREVENTIVE VACCINE MARKET ANALYSIS
    240. BY END USER FIGURE 23. UK PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE
    241. FRANCE PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 25. FRANCE
    242. PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 26. FRANCE
    243. PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 27. FRANCE PREVENTIVE
    244. VACCINE MARKET ANALYSIS BY END USER FIGURE 28. FRANCE PREVENTIVE VACCINE MARKET
    245. ANALYSIS BY REGIONAL FIGURE 29. RUSSIA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE
    246. TYPE FIGURE 30. RUSSIA PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    247. RUSSIA PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 33. RUSSIA PREVENTIVE
    248. VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 34. ITALY PREVENTIVE VACCINE MARKET ANALYSIS
    249. BY VACCINE TYPE FIGURE 35. ITALY PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF
    250. ADMINISTRATION FIGURE 36. ITALY PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE
    251. PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 39. SPAIN PREVENTIVE VACCINE
    252. MARKET ANALYSIS BY VACCINE TYPE FIGURE 40. SPAIN PREVENTIVE VACCINE MARKET ANALYSIS
    253. BY ROUTE OF ADMINISTRATION FIGURE 41. SPAIN PREVENTIVE VACCINE MARKET ANALYSIS BY
    254. TARGET DISEASE FIGURE 42. SPAIN PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE
    255. SPAIN PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 44. REST OF EUROPE
    256. PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 45. REST OF EUROPE PREVENTIVE
    257. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 46. REST OF EUROPE PREVENTIVE
    258. VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 47. REST OF EUROPE PREVENTIVE VACCINE
    259. MARKET ANALYSIS BY END USER FIGURE 48. REST OF EUROPE PREVENTIVE VACCINE MARKET
    260. ANALYSIS BY REGIONAL FIGURE 49. APAC PREVENTIVE VACCINE MARKET ANALYSIS FIGURE 50.
    261. CHINA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 51. CHINA PREVENTIVE
    262. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 52. CHINA PREVENTIVE VACCINE
    263. MARKET ANALYSIS BY TARGET DISEASE FIGURE 53. CHINA PREVENTIVE VACCINE MARKET ANALYSIS
    264. BY END USER FIGURE 54. CHINA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE
    265. INDIA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 56. INDIA PREVENTIVE
    266. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 57. INDIA PREVENTIVE VACCINE
    267. MARKET ANALYSIS BY TARGET DISEASE FIGURE 58. INDIA PREVENTIVE VACCINE MARKET ANALYSIS
    268. BY END USER FIGURE 59. INDIA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE
    269. JAPAN PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 61. JAPAN PREVENTIVE
    270. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 62. JAPAN PREVENTIVE VACCINE
    271. MARKET ANALYSIS BY TARGET DISEASE FIGURE 63. JAPAN PREVENTIVE VACCINE MARKET ANALYSIS
    272. BY END USER FIGURE 64. JAPAN PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE
    273. SOUTH KOREA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 66. SOUTH
    274. KOREA PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 67. SOUTH
    275. KOREA PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 68. SOUTH KOREA
    276. PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 69. SOUTH KOREA PREVENTIVE
    277. VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 70. MALAYSIA PREVENTIVE VACCINE MARKET
    278. ANALYSIS BY VACCINE TYPE FIGURE 71. MALAYSIA PREVENTIVE VACCINE MARKET ANALYSIS
    279. BY ROUTE OF ADMINISTRATION FIGURE 72. MALAYSIA PREVENTIVE VACCINE MARKET ANALYSIS
    280. BY TARGET DISEASE FIGURE 73. MALAYSIA PREVENTIVE VACCINE MARKET ANALYSIS BY END
    281. USER FIGURE 74. MALAYSIA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 75.
    282. THAILAND PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 76. THAILAND
    283. PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 77. THAILAND
    284. PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 78. THAILAND PREVENTIVE
    285. VACCINE MARKET ANALYSIS BY END USER FIGURE 79. THAILAND PREVENTIVE VACCINE MARKET
    286. ANALYSIS BY REGIONAL FIGURE 80. INDONESIA PREVENTIVE VACCINE MARKET ANALYSIS BY
    287. VACCINE TYPE FIGURE 81. INDONESIA PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF
    288. ADMINISTRATION FIGURE 82. INDONESIA PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET
    289. DISEASE FIGURE 83. INDONESIA PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE
    290. INDONESIA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 85. REST OF
    291. APAC PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 86. REST OF APAC
    292. PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 87. REST OF
    293. APAC PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 88. REST OF APAC
    294. PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 89. REST OF APAC PREVENTIVE
    295. VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 90. SOUTH AMERICA PREVENTIVE VACCINE
    296. MARKET ANALYSIS FIGURE 91. BRAZIL PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE
    297. TYPE FIGURE 92. BRAZIL PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    298. BRAZIL PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 95. BRAZIL PREVENTIVE
    299. VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 96. MEXICO PREVENTIVE VACCINE MARKET
    300. ANALYSIS BY VACCINE TYPE FIGURE 97. MEXICO PREVENTIVE VACCINE MARKET ANALYSIS BY
    301. ROUTE OF ADMINISTRATION FIGURE 98. MEXICO PREVENTIVE VACCINE MARKET ANALYSIS BY
    302. TARGET DISEASE FIGURE 99. MEXICO PREVENTIVE VACCINE MARKET ANALYSIS BY END USER
    303. PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 102. ARGENTINA PREVENTIVE
    304. VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 103. ARGENTINA PREVENTIVE
    305. VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 104. ARGENTINA PREVENTIVE VACCINE
    306. MARKET ANALYSIS BY END USER FIGURE 105. ARGENTINA PREVENTIVE VACCINE MARKET ANALYSIS
    307. BY REGIONAL FIGURE 106. REST OF SOUTH AMERICA PREVENTIVE VACCINE MARKET ANALYSIS
    308. BY VACCINE TYPE FIGURE 107. REST OF SOUTH AMERICA PREVENTIVE VACCINE MARKET ANALYSIS
    309. BY ROUTE OF ADMINISTRATION FIGURE 108. REST OF SOUTH AMERICA PREVENTIVE VACCINE
    310. MARKET ANALYSIS BY TARGET DISEASE FIGURE 109. REST OF SOUTH AMERICA PREVENTIVE VACCINE
    311. MARKET ANALYSIS BY END USER FIGURE 110. REST OF SOUTH AMERICA PREVENTIVE VACCINE
    312. MARKET ANALYSIS BY REGIONAL FIGURE 111. MEA PREVENTIVE VACCINE MARKET ANALYSIS FIGURE
    313. GCC COUNTRIES PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 113.
    314. GCC COUNTRIES PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE
    315. GCC COUNTRIES PREVENTIVE VACCINE MARKET ANALYSIS BY TARGET DISEASE FIGURE 115.
    316. GCC COUNTRIES PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 116. GCC COUNTRIES
    317. PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 117. SOUTH AFRICA PREVENTIVE
    318. VACCINE MARKET ANALYSIS BY VACCINE TYPE FIGURE 118. SOUTH AFRICA PREVENTIVE VACCINE
    319. MARKET ANALYSIS BY ROUTE OF ADMINISTRATION FIGURE 119. SOUTH AFRICA PREVENTIVE VACCINE
    320. MARKET ANALYSIS BY TARGET DISEASE FIGURE 120. SOUTH AFRICA PREVENTIVE VACCINE MARKET
    321. ANALYSIS BY END USER FIGURE 121. SOUTH AFRICA PREVENTIVE VACCINE MARKET ANALYSIS
    322. BY REGIONAL FIGURE 122. REST OF MEA PREVENTIVE VACCINE MARKET ANALYSIS BY VACCINE
    323. TYPE FIGURE 123. REST OF MEA PREVENTIVE VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    324. REST OF MEA PREVENTIVE VACCINE MARKET ANALYSIS BY END USER FIGURE 126. REST
    325. OF MEA PREVENTIVE VACCINE MARKET ANALYSIS BY REGIONAL FIGURE 127. KEY BUYING CRITERIA
    326. OF PREVENTIVE VACCINE MARKET FIGURE 128. RESEARCH PROCESS OF MRFR FIGURE 129. DRO
    327. ANALYSIS OF PREVENTIVE VACCINE MARKET FIGURE 130. DRIVERS IMPACT ANALYSIS: PREVENTIVE
    328. VACCINE MARKET FIGURE 131. RESTRAINTS IMPACT ANALYSIS: PREVENTIVE VACCINE MARKET
    329. VACCINE MARKET, BY VACCINE TYPE, 2024 (% SHARE) FIGURE 134. PREVENTIVE VACCINE MARKET,
    330. BY VACCINE TYPE, 2019 TO 2035 (USD Billions) FIGURE 135. PREVENTIVE VACCINE MARKET,
    331. BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) FIGURE 136. PREVENTIVE VACCINE MARKET,
    332. BY ROUTE OF ADMINISTRATION, 2019 TO 2035 (USD Billions) FIGURE 137. PREVENTIVE VACCINE
    333. MARKET, BY TARGET DISEASE, 2024 (% SHARE) FIGURE 138. PREVENTIVE VACCINE MARKET,
    334. BY TARGET DISEASE, 2019 TO 2035 (USD Billions) FIGURE 139. PREVENTIVE VACCINE MARKET,
    335. BY END USER, 2024 (% SHARE) FIGURE 140. PREVENTIVE VACCINE MARKET, BY END USER,
    336. TO 2035 (USD Billions) FIGURE 141. PREVENTIVE VACCINE MARKET, BY REGIONAL,
    337. (% SHARE) FIGURE 142. PREVENTIVE VACCINE MARKET, BY REGIONAL, 2019 TO 2035
    338. (USD Billions) FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS

    Preventive Vaccine Market Segmentation

    • Preventive Vaccine Market By Vaccine Type (USD Billion, 2019-2035)

      • Live Attenuated Vaccines
      • Inactivated Vaccines
      • Subunit Vaccines
      • mRNA Vaccines
      • Toxoid Vaccines

     

    • Preventive Vaccine Market By Route of Administration (USD Billion, 2019-2035)

      • Intramuscular
      • Subcutaneous
      • Oral
      • Intranasal

     

    • Preventive Vaccine Market By Target Disease (USD Billion, 2019-2035)

      • Viral Infections
      • Bacterial Infections
      • Parasitic Infections
      • Fungal Infections

     

    • Preventive Vaccine Market By End User (USD Billion, 2019-2035)

      • Hospitals
      • Clinics
      • Pharmacies
      • Home Care Settings

     

    • Preventive Vaccine Market By Regional (USD Billion, 2019-2035)

      • North America
      • Europe
      • South America
      • Asia Pacific
      • Middle East and Africa

     

    Preventive Vaccine Market Regional Outlook (USD Billion, 2019-2035)

     

     

    • North America Outlook (USD Billion, 2019-2035)

      • North America Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • North America Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • North America Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • North America Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

      • North America Preventive Vaccine Market by Regional Type

        • US
        • Canada
      • US Outlook (USD Billion, 2019-2035)

      • US Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • US Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • US Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • US Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • CANADA Outlook (USD Billion, 2019-2035)

      • CANADA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • CANADA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • CANADA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • CANADA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

    • Europe Outlook (USD Billion, 2019-2035)

      • Europe Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • Europe Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • Europe Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • Europe Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

      • Europe Preventive Vaccine Market by Regional Type

        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Spain
        • Rest of Europe
      • GERMANY Outlook (USD Billion, 2019-2035)

      • GERMANY Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • GERMANY Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • GERMANY Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • GERMANY Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • UK Outlook (USD Billion, 2019-2035)

      • UK Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • UK Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • UK Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • UK Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • FRANCE Outlook (USD Billion, 2019-2035)

      • FRANCE Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • FRANCE Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • FRANCE Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • FRANCE Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • RUSSIA Outlook (USD Billion, 2019-2035)

      • RUSSIA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • RUSSIA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • RUSSIA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • RUSSIA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • ITALY Outlook (USD Billion, 2019-2035)

      • ITALY Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • ITALY Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • ITALY Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • ITALY Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • SPAIN Outlook (USD Billion, 2019-2035)

      • SPAIN Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • SPAIN Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • SPAIN Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • SPAIN Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • REST OF EUROPE Outlook (USD Billion, 2019-2035)

      • REST OF EUROPE Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • REST OF EUROPE Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • REST OF EUROPE Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • REST OF EUROPE Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

    • APAC Outlook (USD Billion, 2019-2035)

      • APAC Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • APAC Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • APAC Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • APAC Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

      • APAC Preventive Vaccine Market by Regional Type

        • China
        • India
        • Japan
        • South Korea
        • Malaysia
        • Thailand
        • Indonesia
        • Rest of APAC
      • CHINA Outlook (USD Billion, 2019-2035)

      • CHINA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • CHINA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • CHINA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • CHINA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • INDIA Outlook (USD Billion, 2019-2035)

      • INDIA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • INDIA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • INDIA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • INDIA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • JAPAN Outlook (USD Billion, 2019-2035)

      • JAPAN Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • JAPAN Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • JAPAN Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • JAPAN Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • SOUTH KOREA Outlook (USD Billion, 2019-2035)

      • SOUTH KOREA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • SOUTH KOREA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • SOUTH KOREA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • SOUTH KOREA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • MALAYSIA Outlook (USD Billion, 2019-2035)

      • MALAYSIA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • MALAYSIA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • MALAYSIA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • MALAYSIA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • THAILAND Outlook (USD Billion, 2019-2035)

      • THAILAND Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • THAILAND Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • THAILAND Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • THAILAND Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • INDONESIA Outlook (USD Billion, 2019-2035)

      • INDONESIA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • INDONESIA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • INDONESIA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • INDONESIA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • REST OF APAC Outlook (USD Billion, 2019-2035)

      • REST OF APAC Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • REST OF APAC Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • REST OF APAC Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • REST OF APAC Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

    • South America Outlook (USD Billion, 2019-2035)

      • South America Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • South America Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • South America Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • South America Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

      • South America Preventive Vaccine Market by Regional Type

        • Brazil
        • Mexico
        • Argentina
        • Rest of South America
      • BRAZIL Outlook (USD Billion, 2019-2035)

      • BRAZIL Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • BRAZIL Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • BRAZIL Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • BRAZIL Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • MEXICO Outlook (USD Billion, 2019-2035)

      • MEXICO Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • MEXICO Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • MEXICO Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • MEXICO Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • ARGENTINA Outlook (USD Billion, 2019-2035)

      • ARGENTINA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • ARGENTINA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • ARGENTINA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • ARGENTINA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

      • REST OF SOUTH AMERICA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • REST OF SOUTH AMERICA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • REST OF SOUTH AMERICA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • REST OF SOUTH AMERICA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

    • MEA Outlook (USD Billion, 2019-2035)

      • MEA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • MEA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • MEA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • MEA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings

      • MEA Preventive Vaccine Market by Regional Type

        • GCC Countries
        • South Africa
        • Rest of MEA
      • GCC COUNTRIES Outlook (USD Billion, 2019-2035)

      • GCC COUNTRIES Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • GCC COUNTRIES Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • GCC COUNTRIES Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • GCC COUNTRIES Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • SOUTH AFRICA Outlook (USD Billion, 2019-2035)

      • SOUTH AFRICA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • SOUTH AFRICA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • SOUTH AFRICA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • SOUTH AFRICA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
      • REST OF MEA Outlook (USD Billion, 2019-2035)

      • REST OF MEA Preventive Vaccine Market by Vaccine Type

        • Live Attenuated Vaccines
        • Inactivated Vaccines
        • Subunit Vaccines
        • mRNA Vaccines
        • Toxoid Vaccines

      • REST OF MEA Preventive Vaccine Market by Route of Administration Type

        • Intramuscular
        • Subcutaneous
        • Oral
        • Intranasal

      • REST OF MEA Preventive Vaccine Market by Target Disease Type

        • Viral Infections
        • Bacterial Infections
        • Parasitic Infections
        • Fungal Infections

      • REST OF MEA Preventive Vaccine Market by End User Type

        • Hospitals
        • Clinics
        • Pharmacies
        • Home Care Settings
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027